Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment‐naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6, CYP3A4, NR1I3) as covariates and explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickinson, L, Amin, J, Else, L, Boffito, M, Egan, D, Owen, A, Khoo, S, Back, D, Orrell, C, Clarke, A, Losso, M, Phanuphak, P, Carey, D, Cooper, DA, Emery, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744681/
https://www.ncbi.nlm.nih.gov/pubmed/26044067
http://dx.doi.org/10.1002/cpt.156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744681/
https://www.ncbi.nlm.nih.gov/pubmed/26044067
http://dx.doi.org/10.1002/cpt.156

Ejemplares similares